Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 5/20 | 0.62 |
| ▸ | CTSL | P07711 | 4/20 | 0.62 |
| ▸ | CTSB | P07858 | 4/20 | 0.62 |
| ▸ | CTSS | P25774 | 3/20 | 0.62 |
| ▸ | ATM | Q13315 | 1/20 | 0.60 |
| ▸ | ELANE | P08246 | 2/20 | 0.56 |
| ▸ | PRTN3 | P24158 | 1/20 | 0.56 |
| ▸ | CASP3 | P42574 | 2/20 | 0.55 |
| ▸ | CA2 | P00918 | 1/20 | 0.55 |
| ▸ | CA5A | P35218 | 1/20 | 0.55 |
| ▸ | CASP1 | P29466 | 1/20 | 0.55 |
| ▸ | CASP7 | P55210 | 1/20 | 0.55 |
| ▸ | CASP6 | P55212 | 1/20 | 0.55 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19465739 | 0.94 | CTSK (0.57) | CTSKCTSLCTSBCTSSATM | |
| SCHEMBL10269278 | 0.92 | CTSK (0.55) | CTSKCTSLCTSBCTSSATM | |
| SCHEMBL10535601 | 0.91 | TRPM8 (0.62) | CTSKCTSLCTSBCTSSATM | |
| SCHEMBL28892051 | 0.91 | TRPM8 (0.62) | CTSKCTSLCTSBCTSSATM | |
| SCHEMBL10535596 | 0.91 | TRPM8 (0.62) | CTSKCTSLCTSBCTSSATM | |
| SCHEMBL12577363 | 0.90 | CTSL (0.52) | CTSKCTSLCTSBCTSSATM | |
| SCHEMBL8671882 | 0.89 | CTSL (0.63) | CTSKCTSLCTSBCTSSATM | |
| SCHEMBL220569 | 0.89 | CTSL (0.63) | CTSKCTSLCTSBCTSSATM | |
| SCHEMBL1287168 | 0.89 | CTSL (0.63) | CTSKCTSLCTSBCTSSATM | |
| SCHEMBL2978398 | 0.89 | CTSL (0.63) | CTSKCTSLCTSBCTSSATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9789118-B2 | Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof | NOVARTIS AG (CH) | 2017-10-17 | — | — | US | disclosed |
| US-9789118-B2 | Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof | NOVARTIS AG (CH) | 2017-10-17 | — | — | US | disclosed |
| EP-2598486-B1 | BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS | NOVARTIS AG (CH) | 2017-06-28 | — | — | EP | disclosed |
| EP-2507210-B1 | CYCLOHEXANE DERIVATIVES AS INHIBITORS OF ACETYL-COA CARBOXYLASE (ACC) | NOVARTIS AG (CH) | 2015-04-08 | — | — | EP | disclosed |
| US-20140171363-A1 | BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS AND USES THEREOF | NOVARTIS AG (CH) | 2014-06-19 | — | — | US | disclosed |
| US-20140171363-A1 | BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS AND USES THEREOF | NOVARTIS AG (CH) | 2014-06-19 | — | — | US | disclosed |
| US-8394858-B2 | Cyclohexane derivatives and uses thereof | NOVARTIS AG (CH) | 2013-03-12 | — | — | US | disclosed |
| EP-2507210-A1 | CYCLOHEXANE DERIVATIVES AS INHIBITORS OF ACETYL-COA CARBOXYLASE (ACC) | Novartis AG (CH) | 2012-10-10 | — | — | EP | disclosed |
| US-20120028969-A1 | BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS AND USES THEREOF | NOVARTIS AG (CH) | 2012-02-02 | — | — | US | disclosed |
| US-20120028969-A1 | BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS AND USES THEREOF | NOVARTIS AG (CH) | 2012-02-02 | — | — | US | disclosed |
| US-5716973-A | ADMINISTERING DIFLUORO STATONE ANALOGS | MERRELL PHARMACEUTICALS INC. (US) | 1998-02-10 | — | — | US | disclosed |
| US-5691368-A | THERAPY FOR NEURODEGENERATIVE DISORDERS | HOECHST MARION ROUSSEL, INC. (US) | 1997-11-25 | — | — | US | disclosed |
| EP-0802909-A2 | SUBSTITUTED OXAZOLIDINE CALPAIN AND/OR CATHEPSIN B INHIBITORS | HOECHST MARION ROUSSEL, INC. (US) | 1997-10-29 | — | — | EP | disclosed |
| US-5559140-A | VIRICIDES | MERRELL PHARMACEUTICALS INC. (US) | 1996-09-24 | — | — | US | disclosed |
| EP-0565631-B1 | ANTI-VIRAL COMPOUNDS | MERRELL PHARMA INC (US) | 1996-09-18 | — | — | EP | disclosed |
| WO-1996021655-A2 | SUBSTITUTED OXAZOLIDINE CALPAIN AND/OR CATHEPSIN B INHIBITORS | HOECHST MARION ROUSSEL, INC. (US) | 1996-07-18 | — | — | WO | disclosed |
| EP-0721449-A1 | INHIBITORS OF $g(b)-AMYLOID PROTEIN PRODUCTION | MERRELL PHARMACEUTICALS INC. (US) | 1996-07-17 | — | — | EP | disclosed |
| WO-1995009838-A1 | INHIBITORS OF β-AMYLOID PROTEIN PRODUCTION | MERRELL PHARMACEUTICALS INC. (US) | 1995-04-13 | — | — | WO | disclosed |
| EP-0565631-A1 | ANTI-VIRAL COMPOUNDS. | MERRELL DOW PHARMA (US) | 1993-10-20 | — | — | EP | disclosed |
| WO-1992012123-A1 | ANTI-VIRAL COMPOUNDS | MERRELL DOW PHARMACEUTICALS INC. (US) | 1992-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140171363-A1 | BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS AND USES THEREOF | ACACA, ACACB, COASY | CTSK 1109/4885CTSL 1870/4885CTSB 1337/4885 |
| US-20120028969-A1 | BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS AND USES THEREOF | ACACA, ACACB, COASY | CTSK 1109/4885CTSL 1870/4885CTSB 1337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.